Jørgen Georgsen

Jørgen Georgsen

Auto-generated profile, based on publicly available information

Jørgen Georgsen

South Danish Transfusion Service, Odense University Hospital, Odense C, Denmark

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2004 in Transfusion
Verified
Journal Article
Closed access
PDF file
LMLars Munksgaard
Lars Munksgaard
LALene Albjerg
Lene Albjerg
SLSøren T. Lillevang
Søren T. Lillevang
BGBente Gahrn‐Hansen
Bente Gahrn‐Hansen
JGJørgen Georgsen
Jørgen Georgsen

29 October 2017 in Vox Sanguinis
Verified
Journal Article
Open access
PDF file
PMPaola Maria Manzini
Paola Maria Manzini
ADA. M. Dall'OMo
A. M. Dall'OMo
SDS. D'ANtico
S. D'ANtico
AVA. Valfrè
A. Valfrè
KPK. Pendry
K. Pendry
KAK. Aranko
K. Aranko
Background and Objectives: The aim of this survey was to evaluate the knowledge about Patient Blood Management (PBM) principles and practices amongst clinicians working in seven European hospitals participating in a European Blood Alliance (EBA) project.Materials and Methods: A web‐based questionnaire was sent to 4952 clinicians working in medical, surgery and anaesthesiology disciplines. The responses were analysed, and the overall results as well as a comparison between hospitals are presented.Results: A total of 788 responses (16%) were obtained. About 24% of respondents were not aware of a correlation between preoperative anaemia (POA) and perioperative morbidity and mortality. For 22%, treatment of POA was unlikely to favourably influence morbidity and mortality even before surgery with expected blood loss. More than half of clinicians did not routinely treat POA. 29%, when asked which is the best way to treat deficiency anaemia preoperatively, answered that they did not have sufficient knowledge and 5% chose to ‘do nothing’. Amongst those who treated POA, 38% proposed red cell transfusion prior to surgery as treatment. Restrictive haemoglobin triggers for red blood cell transfusion, single unit policy and reduction of number and volumes of blood samples for diagnostic purposes were only marginally implemented.Conclusion: Overall, the responses indicated poor knowledge about PBM. Processes to diagnose and treat POA were not generally and homogeneously implemented. This survey should provide further impetus to implement programmes to improve knowledge and practice of PBM.

1 April 2021 in Transfusion Medicine Reviews
Verified
Journal Article
Open access
HRHans Van Remoortel
Hans Van Remoortel
JLJorien Laermans
Jorien Laermans
BABert Avau
Bert Avau
GBGeertruida Bekkering
Geertruida Bekkering
JGJørgen Georgsen
Jørgen Georgsen
PVPhilippe Vandekerckhove
Philippe Vandekerckhove
Patient Blood Management (PBM) is an evidence-based, multidisciplinary, patient-centred approach to optimizing the care of patients who might need a blood transfusion. This systematic review aimed to collect the best available evidence on the effectiveness of preoperative iron supplementation with or without erythropoiesis-stimulating agents (ESAs) on red blood cell (RBC) utilization in all-cause anaemic patients scheduled for elective surgery. Five databases and two trial registries were screened. Primary outcomes were the number of patients and the number of RBC units transfused. Effect estimates were synthesized by conducting meta-analyses. GRADE (Grades of Recommendation, Assessment, Development and Evaluation) was used to assess the certainty of evidence. We identified 29 randomized controlled trials (RCTs) and 2 non-RCTs comparing the effectiveness of preoperative iron monotherapy, or iron + ESAs, to control (no treatment, usual care, placebo). We found that: (1) IV and/or oral iron monotherapy may not result in a reduced number of units transfused and IV iron may not reduce the number of patients transfused (low-certainty evidence); (2) uncertainty exists whether the administration route of iron therapy (IV vs oral) differentially affects RBC utilization (very low-certainty evidence); (3) IV ferric carboxymaltose monotherapy may not result in a different number of patients transfused compared to IV iron sucrose monotherapy (low-certainty evidence); (4) oral iron + ESAs probably results in a reduced number of patients transfused and number of units transfused (moderate-certainty evidence); (5) IV iron + ESAs may result in a reduced number of patients transfused (low-certainty evidence); (6) oral and/or IV iron + ESAs probably results in a reduced number of RBC units transfused in transfused patients (moderate-certainty evidence); (7) uncertainty exists about the effect of oral and/or IV iron + ESAs on the number of patients requiring transfusion of multiple units (very low-certainty evidence). Effect estimates of different haematological parameters and length of stay were synthesized as secondary outcomes. In conclusion, in patients with anaemia of any cause scheduled for elective surgery, the preoperative administration of iron monotherapy may not result in a reduced number of patients or units transfused (low-certainty evidence). Iron supplementation in addition to ESAs probably results in a reduced RBC utilization (moderate-certainty evidence).

1 June 1993 in Transfusion Medicine
Verified
Journal Article
Closed access
PDF file
BAB. R. Andersen
B. R. Andersen
JGJ. Georgsen
J. Georgsen
HMH. O. Madsen
H. O. Madsen
ETE. Taaning
E. Taaning
NGN. Grunnet
N. Grunnet
ASA. Svejgaard
A. Svejgaard

1 January 2005 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Open access
PDF file
RLRune Larsen
Rune Larsen
KTKjell Titlestad
Kjell Titlestad
SLSøren Thue Lillevang
Søren Thue Lillevang
STSten Grove Thomsen
Sten Grove Thomsen
KKKristian Kidholm
Kristian Kidholm
JGJørgen Georgsen
Jørgen Georgsen
Background. Routine pretransfusion testing for red cell alloantibodies (RBCab) in cesarean patients is standard practice in many obstetric centers. The objective of the present study was to evaluate the usefulness of this test. Method. A retrospective study was conducted using computerized registers to extract data on blood transfusions and the occurrence of RBCab in cesarean patients. Results. A total of 4434 admissions for cesarean section were identified. Only 10 patients (0.23%) had clinically significant RBCab, which had not been previously detected. Blood transfusions were required in relation to 147 cesarean sections (3.3%). A number of preoperative conditions, traditionally believed to be risk factors for preoperative and postpartum hemorrhage, occurred more frequently in transfused patients than in nontransfused. The probability of a cesarean patient having a previously undetected clinically significant RBCab and receiving a blood transfusion during admission for delivery was estimated to be 9.0 × 10−5 (1 in 11 050 cesarean sections). Analyses of the time relationships between cesarean sections and initiation of blood transfusions indicated that most often there would be enough time for postoperative antibody screening and/or cross matching if the routine pretransfusion testing was omitted. Conclusion. These findings suggest that routine pretransfusion testing in cesarean patients can be omitted.

17 October 2022 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
JLJorien Laermans
Jorien Laermans
HRHans Van Remoortel
Hans Van Remoortel
BABert Avau
Bert Avau
GBGeertruida Bekkering
Geertruida Bekkering
JGJørgen Georgsen
Jørgen Georgsen
PVPhilippe Vandekerckhove
Philippe Vandekerckhove
Background: Iron supplementation and erythropoiesis-stimulating agent (ESA) administration represent the hallmark therapies in preoperative anemia treatment, as reflected in a set of evidence-based treatment recommendations made during the 2018 International Consensus Conference on Patient Blood Management. However, little is known about the safety of these therapies. This systematic review investigated the occurrence of adverse events (AEs) during or after treatment with iron and/or ESAs.Methods: Five databases (The Cochrane Library, MEDLINE, Embase, Transfusion Evidence Library, Web of Science) and two trial registries (ClinicalTrials.gov, WHO ICTRP) were searched until 23 May 2022. Randomized controlled trials (RCTs), cohort, and case-control studies investigating any AE during or after iron and/or ESA administration in adult elective surgery patients with preoperative anemia were eligible for inclusion and judged using the Cochrane Risk of Bias tools. The GRADE approach was used to assess the overall certainty of evidence.Results: Data from 26 RCTs and 16 cohort studies involving a total of 6062 patients were extracted, on 6 treatment comparisons: (1) intravenous (IV) versus oral iron, (2) IV iron versus usual care/no iron, (3) IV ferric carboxymaltose versus IV iron sucrose, (4) ESA+iron versus control (placebo and/or iron, no treatment), (5) ESA+IV iron versus ESA+oral iron, and (6) ESA+IV iron versus ESA+IV iron (different ESA dosing regimens). Most AE data concerned mortality/survival (n=24 studies), thromboembolic (n=22), infectious (n=20), cardiovascular (n=19) and gastrointestinal (n=14) AEs. Very low certainty evidence was assigned to all but one outcome category. This uncertainty results from both the low quantity and quality of AE data due to the high risk of bias caused by limitations in the study design, data collection, and reporting.Conclusions: It remains unclear if ESA and/or iron therapy is associated with AEs in preoperatively anemic elective surgery patients. Future trial investigators should pay more attention to the systematic collection, measurement, documentation, and reporting of AE data.